Gyre Therapeutics (GYRE) Retained Earnings (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Retained Earnings of -$77.7 million for Q1 2026, down 156.21% year-over-year from $138.2 million in Q1 2025, and down 9870.09% quarter-over-quarter from -$779000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Retained Earnings (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Retained Earnings for 17 consecutive years, with -$77.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 156.21% year-over-year to -$77.7 million; the TTM figure through Mar 2026 stood at -$77.7 million (down 156.21% YoY), while the FY2025 annual figure was -$779000.0, up 98.94% from the prior year.
- Retained Earnings eased to -$77.7 million in Q1 2026 per GYRE's latest filing, from -$779000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $444.6 million in Q2 2022 and bottomed at -$414.7 million in Q3 2023.
- Historically, Retained Earnings has averaged -$64.8 million across 5 years, with a median of -$73.4 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 37050100.0% — and 2025, when it soared 277.15%.
- Gyre Therapeutics' Retained Earnings stood at $7.4 million in 2022, then plunged by 1256.7% to -$85.5 million in 2023, then increased by 14.13% to -$73.5 million in 2024, then surged by 98.94% to -$779000.0 in 2025, then slumped by 9870.09% to -$77.7 million in 2026.
- Business Quant data shows GYRE's Retained Earnings at -$77.7 million in Q1 2026, -$779000.0 in Q4 2025, and -$66.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 240.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.64 Mn |
| Mar 31, 2026 | -77.67 Mn |
| Dec 31, 2025 | -779,000.00 |
| Sep 30, 2025 | -66.70 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | 138.18 Mn |
| Dec 31, 2024 | -73.45 Mn |
| Sep 30, 2024 | -73.40 Mn |
| Jun 30, 2024 | -2.01 Mn |
| Mar 31, 2024 | -78.00 Mn |
| Dec 31, 2023 | -85.54 Mn |
| Sep 30, 2023 | -414.72 Mn |
| Jun 30, 2023 | -413.15 Mn |
| Mar 31, 2023 | -410.68 Mn |
| Dec 31, 2022 | 7.40 Mn |
| Sep 30, 2022 | -370.50 Mn |
| Jun 30, 2022 | 444.63 Mn |
| Mar 31, 2022 | 444.28 Mn |
| Dec 31, 2021 | 443.75 Mn |
| Sep 30, 2021 | 1,000.00 |